Best Biologic for Psoriasis in 2026

Comparing FDA-approved biologics by clearance rates, dosing frequency, mechanism, and cost

Key Takeaways

IL-23 inhibitors (Skyrizi, Tremfya, Ilumya) show the highest PASI 90/100 clearance rates in clinical trials
Bimzelx (dual IL-17A/F inhibitor) has shown impressive short-term clearance in head-to-head trials
All approved psoriasis biologics are significantly more effective than traditional systemic therapies
The best biologic for you depends on your condition, health history, and insurance — not just efficacy data
Most insured patients pay $0–$35/month through copay programs

FDA-Approved Biologics for Plaque Psoriasis

Medication	Class	Dosing	PASI 90 (approx)	Also approved for
Skyrizi	IL-23	Every 12 wks	~90%	PsA, Crohn's
Bimzelx	IL-17A/F	Every 4–8 wks	~91%	PsA, AS
Tremfya	IL-23	Every 8 wks	~80%	PsA
Cosentyx	IL-17A	Monthly	~77%	PsA, AS
Stelara	IL-12/23	Every 12 wks	~67%	PsA, Crohn's, UC
Ilumya	IL-23	Every 12 wks	~69%	Psoriasis only
Sotyktu	TYK2	Once daily oral	~58%	Psoriasis only
Humira	TNF-α	Every 2 wks	~50%	RA, Crohn's, UC, AS, HS
Enbrel	TNF-α	Weekly	~44%	RA, PsA, AS

PASI 90 rates are approximate values from pivotal clinical trials at primary endpoints and vary by trial design. Direct comparisons should be interpreted with caution.

Which Psoriasis Biologic Is Right for You?

Efficacy data is important, but the "best" biologic for psoriasis depends on many factors beyond PASI scores:

You also have PsA or AS

Skyrizi, Cosentyx, Bimzelx, and Tremfya all cover psoriatic arthritis. Cosentyx, Bimzelx, and Humira cover ankylosing spondylitis.

You also have IBD

Avoid IL-17 inhibitors (Cosentyx, Bimzelx) if you have Crohn's or UC — they can worsen IBD. Consider Skyrizi, Stelara, or Humira which are IBD-approved.

You prefer oral medication

Sotyktu (deucravacitinib) is the only oral biologic for psoriasis. No injections required. No routine lab monitoring needed.

Fewer injections preferred

Skyrizi (every 12 weeks = 4 injections/year) and Ilumya (every 12 weeks) offer the least frequent dosing among injectable biologics.

In the head-to-head IMMerge trial, Skyrizi achieved higher PASI 90 and PASI 100 clearance rates than Humira at week 16 and week 52 for plaque psoriasis. Many dermatologists now prefer IL-23 inhibitors like Skyrizi over TNF inhibitors as first-line biologic therapy for psoriasis. However, Humira covers many more conditions (RA, Crohn's, UC, AS, HS), making it a better choice if you have comorbid autoimmune conditions.

Cash list prices range from $4,500–$7,800/month depending on the medication. With commercial insurance and manufacturer copay programs, most patients pay $0–$35/month. BiologicHealthPlus enrolls every patient in all available savings programs at no charge.

Most patients maintain psoriasis control as long as they continue biologic therapy. Some patients experience secondary failure over time (the biologic becomes less effective), often due to the development of anti-drug antibodies. If this occurs, your dermatologist can switch you to a biologic with a different mechanism of action.

💊 BiologicHealthPlus Carries All Psoriasis Biologics

We handle prior authorization, copay enrollment, and free cold-chain delivery for Skyrizi, Tremfya, Cosentyx, Bimzelx, Ilumya, Sotyktu, Humira, and Enbrel.

Psoriasis Treatment Guide →

📚 Sources & Further Reading

Content developed with reference to leading health organizations, peer-reviewed research, and FDA prescribing information.

🔗

Psoriasis Treatment GuidelinesAAD

🔗

Biologic Treatments for PsoriasisNational Psoriasis Foundation

🔗

PsoriasisWikipedia

🔗

IL-23 Inhibitors ReviewNIH/NCBI

Medical Disclaimer: Educational content reviewed by the BiologicHealthPlus Clinical Team. Consult your healthcare provider for personalized advice. Last reviewed: August 2026.

PASI 90 rates are from pivotal trials and should not be used as sole decision-making criteria. Always discuss treatment choices with your dermatologist or rheumatologist. Last updated: July 2026.